Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.

To SQ, Kwan EM, Fettke HC, Mant A, Docanto MM, Martelotto L, Bukczynska P, Ng N, Graham LK, Parente P, Pezaro C, Mahon K, Horvath L, Todenhöfer T, Azad AA.

Eur Urol. 2018 Feb 2. pii: S0302-2838(18)30016-2. doi: 10.1016/j.eururo.2018.01.007. [Epub ahead of print]

PMID:
29398263
2.

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

Khalaf DJ, Avilés CM, Azad AA, Sunderland K, Todenhöfer T, Eigl BJ, Finch D, Le L, Atwell A, Keith B, Kollmannsberger C, Chi KN.

Can Urol Assoc J. 2017 Dec 1. doi: 10.5489/cuaj.4600. [Epub ahead of print]

PMID:
29381456
3.

Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer.

Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN.

Cancer Discov. 2018 Jan 24. pii: CD-17-0937. doi: 10.1158/2159-8290.CD-17-0937. [Epub ahead of print]

PMID:
29367197
4.

Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.

Day D, Kanjanapan Y, Kwan E, Yip D, Lawrentschuk N, Davis ID, Azad AA, Wong S, Rosenthal M, Gibbs P, Tran B.

Intern Med J. 2016 Nov;46(11):1291-1297. doi: 10.1111/imj.13202.

PMID:
27507629
5.

Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma.

Annala M, Nappi L, Azad AA, Mo F, Fazli L, Chi KN, Wyatt AW.

Clin Genitourin Cancer. 2017 Feb;15(1):e145-e150. doi: 10.1016/j.clgc.2016.05.019. Epub 2016 May 27. No abstract available.

PMID:
27324055
6.

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

Wyatt AW, Azad AA, Volik SV, Annala M, Beja K, McConeghy B, Haegert A, Warner EW, Mo F, Brahmbhatt S, Shukin R, Le Bihan S, Gleave ME, Nykter M, Collins CC, Chi KN.

JAMA Oncol. 2016 Dec 1;2(12):1598-1606. doi: 10.1001/jamaoncol.2016.0494.

7.

Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.

Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, Singh K, Azad AA, Wyatt AW, LeBihan S, Chi KN, Gleave ME, Rennie PS, Collins CC, Cherkasov A.

Genome Biol. 2016 Jan 26;17:10. doi: 10.1186/s13059-015-0864-1.

8.

Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression.

Crea F, Quagliata L, Michael A, Liu HH, Frumento P, Azad AA, Xue H, Pikor L, Watahiki A, Morant R, Eppenberger-Castori S, Wang Y, Parolia A, Lennox KA, Lam WL, Gleave M, Chi KN, Pandha H, Wang Y, Helgason CD.

Mol Oncol. 2016 May;10(5):693-703. doi: 10.1016/j.molonc.2015.12.010. Epub 2015 Dec 22.

9.

Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.

Leibowitz-Amit R, Pintilie M, Khoja L, Azad AA, Berger R, Laird AD, Aftab DT, Chi KN, Joshua AM.

J Transl Med. 2016 Jan 13;14:12. doi: 10.1186/s12967-015-0747-y.

10.

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.

Chi KN, Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, Rathkopf DE, Fizazi K, Kantoff PW, Li J, Azad AA, Eigl BJ, Heng DY, Joshua AM, de Bono JS, Scher HI.

Ann Oncol. 2016 Mar;27(3):454-60. doi: 10.1093/annonc/mdv594. Epub 2015 Dec 18.

11.

Clinical Evaluation of Proximal Contact Points in Fixed Prostheses.

Akhtar Q, Danyal S, Zareen S, Ahmed B, Maqsood M, Azad AA.

J Coll Physicians Surg Pak. 2015 Sep;25(9):702-4. doi: 09.2015/JCPSP.702704.

PMID:
26374372
12.

Patterns of care for metastatic renal cell carcinoma in Australia.

Day D, Kanjanapan Y, Kwan E, Yip D, Lawrentschuk N, Andrews M, Davis ID, Azad AA, Rosenthal M, Wong S, Johnstone A, Gibbs P, Tran B.

BJU Int. 2015 Oct;116 Suppl 3:36-41. doi: 10.1111/bju.13176. Epub 2015 Jul 21.

13.

Governance and management of national telehealth programs in Asia.

Marcelo A, Ganesh J, Mohan J, Kadam DB, Ratta BS, Kulatunga G, John S, Chandra A, Primadi O, Mohamed AA, Khan MA, Azad AA, Marcelo P.

Stud Health Technol Inform. 2015;209:95-101.

PMID:
25980710
15.

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.

Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, Small EJ, Wang Y, Gleave ME, Collins CC, Chi KN.

Clin Cancer Res. 2015 May 15;21(10):2315-24. doi: 10.1158/1078-0432.CCR-14-2666. Epub 2015 Feb 23.

16.

Targeting heat shock proteins in metastatic castration-resistant prostate cancer.

Azad AA, Zoubeidi A, Gleave ME, Chi KN.

Nat Rev Urol. 2015 Jan;12(1):26-36. doi: 10.1038/nrurol.2014.320. Epub 2014 Dec 16. Review.

PMID:
25512207
17.

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.

Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, Zoubeidi A.

Oncotarget. 2015 Jan 1;6(1):234-42.

18.

Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer.

Zielinski RR, Azad AA, Chi KN, Tyldesely S.

Can Urol Assoc J. 2014 Jul;8(7-8):E520-3. doi: 10.5489/cuaj.2076.

19.

A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.

Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN.

Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872. Epub 2014 Aug 29.

PMID:
25175831
20.

Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.

Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN.

Eur Urol. 2015 Jan;67(1):23-29. doi: 10.1016/j.eururo.2014.06.045. Epub 2014 Jul 10.

PMID:
25018038
21.

Discharge patterns, survival outcomes, and changes in clinical management of hospitalized adult patients with cancer with a do-not-resuscitate order.

Azad AA, Siow SF, Tafreshi A, Moran J, Franco M.

J Palliat Med. 2014 Jul;17(7):776-81. doi: 10.1089/jpm.2013.0554. Epub 2014 May 27.

PMID:
24865307
22.

Metastatic large-cell neuroendocrine prostate carcinoma: successful treatment with androgen deprivation therapy.

Azad AA, Jones EC, Chi KN.

Clin Genitourin Cancer. 2014 Aug;12(4):e151-3. doi: 10.1016/j.clgc.2014.03.006. Epub 2014 Mar 26. No abstract available.

PMID:
24787970
23.

A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.

Azad AA, Beardsley EK, Hotte SJ, Ellard SL, Klotz L, Chin J, Kollmannsberger C, Mukherjee SD, Chi KN.

Invest New Drugs. 2014 Aug;32(4):746-52. doi: 10.1007/s10637-014-0091-8. Epub 2014 Mar 28.

PMID:
24671507
24.

Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.

Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, Clayton R, Heng DY, Joshua AM, Chi KN.

Eur Urol. 2015 Mar;67(3):441-7. doi: 10.1016/j.eururo.2014.01.030. Epub 2014 Jan 31.

PMID:
24508071
25.

A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.

Lau DK, Andrews MC, Turner N, Azad AA, Davis ID, Cebon JS.

Melanoma Res. 2014 Apr;24(2):144-9. doi: 10.1097/CMR.0000000000000036.

PMID:
24463460
26.

Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome?

Azad AA, Eigl BJ.

Eur Urol. 2014 Feb;65(2):504-5. doi: 10.1016/j.eururo.2013.10.035. Epub 2013 Nov 1. No abstract available.

PMID:
24210911
27.
28.

Advantages of multiplex proteomics in clinical immunology: the case of rheumatoid arthritis: novel IgXPLEX™: planar microarray diagnosis.

Lea P, Keystone E, Mudumba S, Kahama A, Ding SF, Hansen J, Azad AA, Wang S, Weber D.

Clin Rev Allergy Immunol. 2011 Aug;41(1):20-35. doi: 10.1007/s12016-009-8189-z.

PMID:
19997988
29.
31.

Solution structure of peptides from HIV-1 Vpr protein that cause membrane permeabilization and growth arrest.

Yao S, Torres AM, Azad AA, Macreadie IG, Norton RS.

J Pept Sci. 1998 Nov;4(7):426-35.

PMID:
9851370
32.

Structural requirements for the cytotoxicity of the N-terminal region of HIV type 1 Nef.

Curtain CC, Lowe MG, Macreadie IG, Gentle IR, Lawrie GA, Azad AA.

AIDS Res Hum Retroviruses. 1998 Nov 20;14(17):1543-51.

PMID:
9840287
33.
34.

Cytotoxic activity of the amino-terminal region of HIV type 1 Nef protein.

Curtain CC, Lowe MG, Arunagiri CK, Mobley PW, Macreadie IG, Azad AA.

AIDS Res Hum Retroviruses. 1997 Sep 20;13(14):1213-20.

PMID:
9310288
35.

HIV-1 protein Vpr causes gross mitochondrial dysfunction in the yeast Saccharomyces cerevisiae.

Macreadie IG, Thorburn DR, Kirby DM, Castelli LA, de Rozario NL, Azad AA.

FEBS Lett. 1997 Jun 30;410(2-3):145-9.

36.

Solution structure of a polypeptide from the N terminus of the HIV protein Nef.

Barnham KJ, Monks SA, Hinds MG, Azad AA, Norton RS.

Biochemistry. 1997 May 20;36(20):5970-80.

PMID:
9166767
37.

Cytotoxicity resulting from addition of HIV-1 Nef N-terminal peptides to yeast and bacterial cells.

Macreadie IG, Lowe MG, Curtain CC, Hewish D, Azad AA.

Biochem Biophys Res Commun. 1997 Mar 27;232(3):707-11.

PMID:
9126340
38.

Extracellular addition of a domain of HIV-1 Vpr containing the amino acid sequence motif H(S/F)RIG causes cell membrane permeabilization and death.

Macreadie IG, Arunagiri CK, Hewish DR, White JF, Azad AA.

Mol Microbiol. 1996 Mar;19(6):1185-92.

PMID:
8730861
39.

The hepatitis B virus X protein is a potent AMP kinase.

Dopheide TA, Azad AA.

J Gen Virol. 1996 Feb;77 ( Pt 2 ):173-6.

PMID:
8627219
40.

Stress- and sequence-dependent release into the culture medium of HIV-1 Nef produced in Saccharomyces cerevisiae.

Macreadie IG, Castelli LA, Lucantoni A, Azad AA.

Gene. 1995 Sep 11;162(2):239-43.

PMID:
7557436
41.

A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects.

Macreadie IG, Castelli LA, Hewish DR, Kirkpatrick A, Ward AC, Azad AA.

Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2770-4.

42.

Expression and analysis of the NS2 protein of influenza A virus.

Ward AC, Castelli LA, Lucantoni AC, White JF, Azad AA, Macreadie IG.

Arch Virol. 1995;140(11):2067-73.

PMID:
7503702
43.

Changes in the NS gene of neurovirulent strains of influenza affect splicing.

Ward AC, Azad AA, McKimm-Breschkin JL.

Virus Genes. 1995;10(1):91-4.

PMID:
7483294
44.

Fusogenic activity of amino-terminal region of HIV type 1 Nef protein.

Curtain CC, Separovic F, Rivett D, Kirkpatrick A, Waring AJ, Gordon LM, Azad AA.

AIDS Res Hum Retroviruses. 1994 Oct;10(10):1231-40.

PMID:
7848681
45.

High-level secretion of correctly processed beta-lactamase from Saccharomyces cerevisiae using a high-copy-number secretion vector.

Castelli LA, Mardon CJ, Strike PM, Azad AA, Macreadie IG.

Gene. 1994 May 3;142(1):113-7.

PMID:
8181744
46.
47.

Large-scale production and characterization of recombinant human immunodeficiency virus type 1 Nef.

Azad AA, Failla P, Lucantoni A, Bentley J, Mardon C, Wolfe A, Fuller K, Hewish D, Sengupta S, Sankovich S, et al.

J Gen Virol. 1994 Mar;75 ( Pt 3):651-5.

PMID:
8126463
48.

Expression and characterisation of the influenza A virus non-structural protein NS1 in yeast.

Ward AC, Azad AA, Macreadie IG.

Arch Virol. 1994;138(3-4):299-314.

PMID:
7998836
49.

Expression and RNA dependent RNA polymerase activity of birnavirus VP1 protein in bacteria and yeast.

Macreadie IG, Azad AA.

Biochem Mol Biol Int. 1993 Aug;30(6):1169-78.

PMID:
8220261
50.

Expression of HIV-1 nef in yeast: the 27 kDa Nef protein is myristylated and fractionates with the nucleus.

Macreadie IG, Ward AC, Failla P, Grgacic E, McPhee D, Azad AA.

Yeast. 1993 Jun;9(6):565-73.

PMID:
8346672

Supplemental Content

Support Center